RECENTLY ADDED

  • ASAM 49th Annual Conference - Innovations in Addiction Medicine and Science - 2018 (63 CME)

    Contains 49 Product(s) 8 new product(s) added recently

    The nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine.


    image

    The ASAM 49th Annual Conference is the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine. The 2018 program includes more education offerings such as; seven concurrent sessions offerings at a time instead of six, three pre-conference courses instead of two.  There will also be three Plenary Sessions that include the popular Opening Plenary Session and Policy Plenary Session and new this year the National Perspectives Plenary Session moderated by the ASAM president with leaders from national federal agencies. There will be other exciting changes to provide learning in a more interactive, casual and fun environment. 

    Learning Objectives:

    At the conclusion of the conference, participants should be able to:

    • Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
    • Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
    • Analyze new research and science to develop practical applications for treatment or further research.
    • Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
    • Create a network of professionals or a set of resources that can be used to support the participant's practice.


    Accreditation Council for Continuing Medical Education (ACCME)

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    The ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science

    The American Society of Addiction Medicine designates this enduring material for a maximum of 71 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (Tmoc)

    This course has been approved by the American Board of Addiction Medicine (ABAM).  Physicians enrolled in the ABAM Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 71 AMA PRA Category 1 Credit(s)™ for completing the The ASAM 48th Annual Conference – Innovations in Addiction Medicine and Science.

    American Psychological Association (APA)

    The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    CME Committee Members

    • Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair
    • Catherine Friedman, MD, FASAM, Vice-Chair
    • Noel Ilogu, MD, MRCP, FASAM
    • Herbert L. Malinoff, MD, FACP, DFASAM
    • Edwin A. Salsitz, MD, DFASAM
    • John C. Tanner, DO, CCFC, DFASAM

    Staff - Sandy Metcalfe, Consultant, ASAM CME Committee, Professional Development Department

    CME Committee, Program Planning Committee and Faculty Disclosure Information

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Who Should Attend:

    • Physicians and Clinicians
    • Researchers and Academics
    • Counselors and Students
    • Other Health Care Professionals 

    dedicated to increasing access and improving the quality of addiction treatment and care.

  • From Overdose to Engagement: Working with First Responders and Emergency Departments (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning how professionals in Indiana's Project POINT have been removing as many barriers as possible to help patients get the services they desire, as well as, getting and then, maintaining engagement in treatment, from this conference recording at The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn about how emergency department (ED) visits for opioid overdose have increased dramatically over the last several years, mirroring trends in overdose related mortality (1). In Indianapolis alone, our ambulance service—Indianapolis Emergency Medical Services—responded to over 2,000 opioid overdoses in 2016 and are on track to outpace that in 2017. Many local public health and safety agencies have championed increased access to naloxone and participated in trainings making it more widely available and accepted by first responders and community members (2). In Indianapolis, we created project POINT to help link those surviving an opioid overdose with the highest quality emergency care including warm hand offs to on-going treatment. Methods: We convened a group of experts and key stakeholders in our hospital system/community and undertook a quality improvement process to improve the care of overdose survivors while in the ED and through their transition to longitudinal care. Results: We developed a set of core ED services and a plan to implement each of them. Core ED services included: 1) brief assessment by a specialty trained outreach team member (ideally a recovery coach), 2) rapid HIV/hepatitis C testing, 3) naloxone teaching and provision, 3) harm reduction counseling, 4) referral to appropriate next level of care and 5) rapid ED follow up focused on recovery support, increasing/supporting motivation and overcoming logistical barriers. We also created a network of providers who were willing and able to accept our referrals and worked with them to optimize the referral process. 

    Conclusions: With the growing opioid epidemic, EDs and EMS systems are looking for novel and effective ways to reduce mortality and help bridge patients into recovery. EDs and EMS systems are used to working at all hours, in austere conditions with complex and often critically ill patients. We offer an expansive and largely untapped network of providers which could be brought to bear on this epidemic. Project POINT is one example of how the ED can help drive incremental change—even in areas of the country where access to high quality MAT is limited.

    Melissa A. Reyes

    MA, CRC

    Melissa Reyes, M.A., CRCMelissa Reyes completed her B.A. in Criminal Justice and Criminology at Ball State University in Muncie, IN. Following graduation, she worked as a case manager for the Madison Co. Problem Solving Courts for two years and was involved with both the Drug Court and Mental Health Court. In 2014, she then pursued her M.A. degree at Michigan State University in Rehabilitation Counseling. Melissa transitioned back to her home state of IN with the acceptance of a care coordinator position with Midtown Adult Addictions in Indianapolis, IN in September of 2016. The position was the forerunner of its kind for both organizations, and required constructing a unique collaboration between the community mental health center and Eskenazi Health ED; the area’s safety-net hospital. By January 2017, Melissa had accepted the role of Program Director for Project POINT (Planned Outreach,Intervention, Naloxone, and Treatment). Initially, POINT focused exclusively on providing referrals with warm handoffs, but Melissa expanded the scope and pursued a more holistic approach. This included promoting the start of implementing harm reduction counseling, rapid HIV/HCV testing as well as take home naloxone kits. In March of 2017, POINT expanded to include peer recovery coaching, and Melissa not only oversees the implementation of this new role, but also develops the training and supervision plan. Most recently, in January 2018, Melissa was offered and accepted the position of Project Director, Project POINT and Mobile Project POINT.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Treating Youth with Opioid Addiction: Cases and Controversies (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to treat youth with opioid addiction while employing developmentally specific approaches, using relapse prevention medication (MAT), from this conference recording from The ASAM 49th Annual Conference (2018).. The session also includes when and how to involve families, as well as a discussion on issues in confidentiality and the use of various levels of care.

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about more about treating youth with opioid addiction through cases and controversies. Young people are disproportionately affected by the current opioid epidemic, with catastrophic consequences for youth and their families. Despite the urgent need, there is a lack of consensus about treatment approaches for youth. Many practitioners have questions, and struggle with this “mysterious” and difficult to engage population. This workshop will feature an interactive, case-based format. Workshop leaders will present 4-5 cases with background and treatment course, each punctuated by “what would you do next…” management questions for guided discussion at several pivotal decision points in the course. Cases are chosen to reflect real world concerns and clinical conundrums, key learning objectives, practice debates and controversies. 

    The goal is to engage participants in a lively conversation about developmentally-informed strategies, approaches, and treatment options in the treatment of this critical target population. 

    Featured cases

    • 18 M at 5th episode of residential detoxification who has been unable to sustain continuing outpatient care despite previous course of buprenorphine.
    • 19 F who becomes pregnant during treatment with extended release naltrexone.
    • 20 M in outpatient treatment, abstinent from opioids on buprenorphine, but struggling with cocaine and other non-opioid substances, opposes communication with family.
    • 17 F who presents in crisis to residential treatment seeking detoxification, and struggles with the process of decision making around recommendations for and choice of relapse prevention medications (buprenorphine vs extended release naltrexone).
    • 18 M with sickle cell anemia with repeated relapses despite multiple treatment levels of care, including multiple attempts at outpatient buprenorphine treatment under various programmatic conditions.

    The case discussions will cover a range of questions, including: 

    1. developmentally specific approaches to treatment of adolescents and young adults with OUDs; 
    2. use of relapse prevention medication (MAT) in youth; 
    3. the role of families, when and how to involve them; 
    4. confidentiality; use of various levels of care; 
    5. the impact of other substance use disorders (primarily cannabis and alcohol); 
    6. delivery models for medications and psychosocial treatment modalities; and others.

    Marc Fishman

    MD, DFASAM

    Marc Fishman MD is a specialist in addiction psychiatry and addiction medicine. He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth. 

    Dr. Fishman served as a co-editor for the most recent editions of ASAM's Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and also a current member of the Board.

    Bikash Sharma

    MD

    Bikash Sharma, MD is currently a medical director for adult services at the Mountain Manor Baltimore, Maryland Treatment Centers.  Dr. Sharma has board certifications with the American Board of Psychiatry and Neurology as well as the American Board of Addiction Psychiatry.  He has been published in numerous journals where he has written about opioid use disorders, and alcohol and substance use in African Americans.  


    Ann Bruner

    MD

    Ann Bruner, MD is a Medical Director, who treats youth at the Mountain Manor Baltimore, Maryland Treatment Centers.  Dr. Bruner is referenced as an author or co-author in dozens of peer-reviewed journals in the Journal of Adolescent Health, and a contributor to the Clinical Handbook of Adolescent Addiction.  

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Dearborn, MI - Wednesday, June 6, 2018

    Contains 2 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    image

    Wednesday, June 6, 2018 | 8:00 am - 5:00 pm
    Double Tree by Hilton Hotel Detroit - Dearborn
    5801 Southfield Fwy
    Detroit, MI 48228

    Cost: $199

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. Please LOG IN to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

    This 8-hour live course covers all treatments and medications for opioid use disorder, and is designed for licensed physician assistants, nurse practitioners, and physicians who plan to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

    Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physician Assistants & Nurse Practitioners

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat opioid use disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

    This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

    For NPs (CE Credit through AANP): Click Here
    For PAs (AAPA Category 1 CME Credit): Click Here

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.


    Click here to view additional resources.

    Upon completion of the live course, you will be able to claim CME Credit through the ASAM e-Learning Center after completing the evaluation module. 

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: July 2018

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits


    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period.

    This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.



    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None



    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee


    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma


    Orexo
    Consulting Fee

    Honorarium
    Content Expert

    Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    At the conclusion of this activity, learners should be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

    Licensed physicians, nurse practitioners, and physician assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.



    1. Fill out the survey by clicking the blue “Fill out Survey” button in the box titled “The ASAM Treatment of Opioid Use Disorder Course Live Portion Evaluation” at the end of the training. 

      1. Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window

    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)

    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”

    4. Choose the type of credit (Physician or Non-physician) and click submit

    5. Click the button “View/Print Certificate” to save or print your certificate
      1. Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)


    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Click here for more information on applying for a waiver to prescribe buprenorphine.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Webinar: Addiction Medicine: The Next Generation (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will cover what an addiction medicine specialist looks like, the different settings an addiction medicine clinician can work in, and the future pathways physician will have to become board-certified in Addiction Medicine.

    Addiction Treatment Week

    This on-demand webinar will cover what an addiction medicine specialist looks like, the different settings an addiction medicine clinician can work in, and the future pathway physician have to become ADM certified.

    This webinar is ideal for pre-medical student, medical students, residents, and medical school administrators.

    Upon completion of this activity, participants will be able to:

    1. Explain recent updates to the Addiction Medicine field.
    2. Describe how changes to the certification process further integrate addiction treatment into the health care system.
    3. Appraise which pathways they are eligible to the ABPM ADM exam. 
    4. Define the different pathways a physician can take from to the ABPM exam. 
    5. Identify the need for more physicians to become board-certified in addiction medicine. 
    6. Explain the basic components of an addiction medicine specialist. 

    Louis E. Baxter, Sr.

    MD, DFASAM

    Dr. Louis E. Baxter, Sr., MD, DFASAM is a Past ASAM President and is the President &CEO of thr Professional Assistance Program of New Jersey, Inc.

    Dr. Baxter is a certified in Addiction Medicine by the American Board of Addiction Medicine and formerly served on the Board of Directors. Dr. Baxter has served and chaired many government advisory committees and panels which include SAMHSA, NIDA, CSAT, NIAAA, and a Presidential Advisor through ONDCP since the Clinton Administration.

    Dr. Baxter has served the State of New Jersey in various capacities serving on the Governor's Council for Drug and Alcohol Addiction, Medical Director for the Division of Addiction Services, and most recently as the Addiction Medicine Consultant for the Division of Mental Health and Addiction Services. He has held academic appointments as Assistant Clinical Professor of Medicine for former University Medicine & Dentistry and now currently with Rutgers New Jersey Medical School in Newark, NJ. Dr. Baxter is serving as Co-Director if the Addiction Medicine Fellowship Program at Howard University Medical School and Hospital.

    Helen E. Jack

    MD

    Helen Jack is a fourth year student at Harvard Medical School. In medical school, her research has focused on how lay health workers, including recovery coaches and community health workers, can contribute to care access and outcomes. She also helps organize the Student Coalition on Addiction, a group of medical students from across Massachusetts engaged in advocacy on addiction medicine education and access to treatment services. She holds a Visiting Researcher position at the Institute of Psychology, Psychiatry, and Neuroscience at King's College London. With KCL, she conducts mental health systems research in Zimbabwe and works on a Wellcome Trust-funded project to build mental health research capacity in southern Africa. Helen graduated from Yale University in 2012. Following graduation, she got a second BA in Philosophy, Politics, and Economics at Oxford University as a Rhodes Scholar. 

    Anna Lembke

    MD, FASAM

    Dr. Anna Lembke is currently an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine.  She is a diplomate of the American Board of Psychiatry and Neurology, a diplomate of the American Board of Addiction Medicine, the Program Director for the Stanford University Addiction Medicine Fellowship, and Chief of the Stanford Addiction Medicine Dual Diagnosis Clinic.

    She has published peer-reviewed articles, chapters, and commentaries, including in the New England Journal of Medicine, the Journal of the American Medical Association, the Journal of General Internal Medicine, and Addiction. Dr. Lembke sees patients, teaches, and does research. She is the author of a book on the prescription drug epidemic: “Drug Dealer, MD: How Doctors Were Duped, Patients Got Hooked, and Why It’s So Hard to Stop” (Johns Hopkins University Press, October 2016).


    Addiction Medicine:  The Next Generation Webinar Planning Committee 

    Name

    Disclosure

    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM

    Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    No Financial Relationships or Conflicts of Interest

    Mark P. Schwartz, MD, FAAFP, DFASAMNo Financial Relationships or Conflicts of Interest
    Louis E. Baxter, MD, DFASAMNo Financial Relationships or Conflicts of Interest
    Helen JackNo Financial Relationships or Conflicts of Interest
    Anna Lembke, MD, FASAMNo Financial Relationships or Conflicts of Interest

    ASAM CME Committee 

    Name

    Disclosure

    Catherine Friedman, MD, FAPA, FASAM, Chair

    No Financial Relationships or Conflicts of Interest

    Adam J. Gordon, MD, MPH, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Noel Ilogu, MD, MRCP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Herbert L. Malinoff, MD, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Edwin A. Salsitz, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/SpeakerCommercial Interest Definition


    A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

     

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.